Pharmacovigilance Is The Study Of Two Primary Outcomes In The Pharmaceutical Industry

Safety And Efficacy


Pharmacovigilance is a top priority in healthcare around the world.

What is Pharmacovigilance?

The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.

Aims of Pharmacovigilance

  • Early detection of drug safety problems.
  • Identify previously unrecognized adverse effects or changes in the patterns of adverse effects.
  • Assess the risks and benefits of medicines in order to determine what action, if any, is necessary to improve their safe use.
  • Improve patient care and patient safety.
  • To promote effective communication to the public.
  • Communication with international institutions working in Pharmacovigilance.
  • Vision

    To ensure patient health care through increasing the effectiveness and safety of our medicinal products.


    One of the primary goals is to ensure the safety and quality of all its medicinal products. As the WNB's Pharmacovigilance department seeks to make a continuous evaluation of the benefit / risk balance to all of our marketed products that is actually used by the patients.

    Pharmacovigilance Department

    WNB realizes that new information always appears and it can have an impact on the benefit / risk balance of any of our marketed products. One of the most important goals of Pharmacovigilance is to make a detailed and comprehensive evaluation of this information to ensure the safe use of all products. This is why WNB established the PV department.

    Part from the Pharmacovigilance department’s responsibilities is to specify and collect information about any adverse drug reactions related to the use of any of our products then analyze it properly to prevent these events from happening again and to make our products safer for the patients.


  • Collects Adverse Drug Reaction & follow up and report these ADRs to the Egyptian Pharmaceuticals Vigilance Center (EPVC).
  • Acts in collaboration with the EPVC as a single contact point for the competent authorities on a 24 Hours basis and set adequate system for out of hour’s coverage.
  • Ensuring conduct of PV and submission of all PV-related documents in accordance with the National legal requirements and Good Pharmacovigilance Practice (GVP) in Arab Countries.
  • Conducts training of PV policies to all colleagues in our company to increase PV awareness and ensure accurate and effective system in reporting safety data.
  • PV involved in the registration process of all company products by preparing Risk Management Plans.
  • Reporting

    Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

    WNB is reminding HCP and public to report any safety information regarding its medicinal products including adverse drug reactions, medications errors, lack of efficacy and other medicine related problems through the following,